Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMMULOGIC -- Ignore unavailable to you. Want to Upgrade?

To: john b who wrote (210)	11/24/1997 6:56:00 PM
From: Bosco	Read Replies (1) \| Respond to of 305

John - thx for the heads-up. I think it can be spinned either way (good or bad.) Now I know why the MM let me ve it for the BID! biz.yahoo.com Let's see the ups and downs of the situation: up: 1. cost conservation 2. HQ is brought in (and you know what investment bankers do) 3. ragweed is pretty dead anyway 4. IND for the coke vaccine 5. nicotine vaccine is a new one not known to people not following the co 6. there is some mgt leadership and initiatives - and Dr Marr didn't wait until $%^& hits the fan 7. $3M/yr burnt rate should ensure no shr dilution for awhile (with $54M endowment left) down: 1. the street never likes surprises 2. allervax used to be the identity of the co, now, it has to convince that street that this is well thought of 3. CAT vaccine is mothballed with RAGWEED 4. Highly unlikely there is a sugar daddy Now that I am doubled down, I obviously hope the ups win out, but I am not sure the street likes surprises. rgds Bosco

To: john b who wrote (210)	11/24/1997 7:16:00 PM
From: Bosco	Read Replies (2) \| Respond to of 305

John & all - My conclusion is hughly +ve after rereading the PR a couple of times. My rationale is this: IMHO, IMUL is trying to convey to the investment community it is ready to shed its ivory tower image and focus on commercialization. The Company concluded that the significant additional costs necessary to commercialize the products were not justified in light of the Company's other strategic alternatives. The Company will continue its technical efforts on two programs: vaccines for drugs of abuse and recombinant proteins directed to the diagnosis and treatment of allergic diseases. As part of the restructuring, the Company intends to reduce headcount and sublease the majority of its space in its Waltham facility. After implementation, the savings from the restructuring will decrease the net cash spend to approximately $3 million annually. The cash resources saved by these actions will permit the Company to pursue other alternatives and it has retained Hambrecht & Quist to assist in this process. As of September 30, 1997, the Company had approximately $54 million in cash and investments. ImmuLogic is focused on developing treatments for allergies and substance abuse. ImmuLogic has a comprehensive worldwide patent portfolio covering the recombinant production of the most common environmental allergens. The Company recently filed an IND for its cocaine vaccine and has an ongoing nicotine vaccine research program. I think this above quoted portion of the PR speaks for itself rgds Bosco